Airway Therapeutics is a biopharmaceutical company based in Cincinnati, OH, dedicated to developing a new class of biologics that target respiratory and inflammatory diseases. Their innovative approach aims to break the cycle of injury and inflammation in patients, offering potential relief and improved outcomes.
One of their key products, zelpultide alfa AT-100, is a novel recombinant human protein that reduces inflammation and infection while modulating the immune response. This engineered version of the endogenous protein hSP-D shows promise in addressing bronchopulmonary dysplasia (BPD), a respiratory disease that affects very preterm infants and can lead to long-term lung damage and other complications.
Generated from the website